Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Journal of Heart Failure

• Publication date

  2004-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejheart.2004.03.001PMID 15302013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

  2005cited by this paper
• Analysing Survival Data from Clinical Trials and Observational Studies

  2005cited by this paper
• Modelling Survival Data in Medical Research

  2004cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  2004cited by this paper
• The Statistical Analysis of Failure Time Data

  2003cited by this paper
• Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry).

  2002cited by this paper
• Dietary n-3 polyunsaturated fatty acids and coronary heart disease-related mortality: a possible mechanism of action

  2002cited by this paper
• Cardiac Membrane Fatty Acid Composition Modulates Myocardial Oxygen Consumption and Postischemic Recovery of Contractile Function

  2002cited by this paper
• Molecular and genetic aspects of cardiac fatty acid homeostasis in health and disease.

  2002cited by this paper
• Statins and chronic heart failure: do we need a large-scale outcome trial?

  2002cited by this paper
• Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction: Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione

  2002cited by this paper
• Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure.

  2002cited by this paper
• Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Blood levels of long-chain n-3 fatty acids and the risk of sudden death.

  2002cited by this paper
• Fish and omega-3 fatty acid intake and risk of coronary heart disease in women.

  2002cited by this paper
• Congestive heart failure: a half century perspective

  2001influential reference
• n-3 Polyunsaturated Fatty Acids, Fish, and Nonfatal Acute Myocardial Infarction

  2001cited by this paper
• n-3 polyunsaturated fatty acids and cardiovascular diseases.

  2001cited by this paper
• Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ‐2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001

  2001cited by this paper
• The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease.

  2001cited by this paper
• n−3 Polyunsaturated fatty acids and cardiovascular diseases: To whom, how much, preparations

  2001cited by this paper
• Amelioration of Angiotensin II–Induced Cardiac Injury by a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor

  2001cited by this paper
• The Denolin lecture. Congestive heart failure: a half century perspective.

  2001cited by this paper
• Guidelines for the diagnosis and treatment of chronic heart failure.

  2001cited by this paper
• Perspectives on n-3 PUFAs: primary prevention, antiarrhythmic effects, congestive heart failure

  2001cited by this paper
• The electrophysiological basis for the antiarrhythmic actions of polyunsaturated fatty acids

  2001cited by this paper
• Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)

  2000cited by this paper
• Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.

  2000cited by this paper
• THE EFFECT OF CARVEDILOL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE

  2000cited by this paper
• Effects of HMG‐COA reductase inhibitors (statins) in patients with heart failure

  2000cited by this paper
• The endotoxin-lipoprotein hypothesis.

  2000cited by this paper
• The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

  2000cited by this paper
• Effects of Lovastatin and Pravastatin on the Survival of Hamsters With Inherited Cardiomyopathy

  2000cited by this paper
• Prevention of Sudden Cardiac Death by Dietary Pure ω-3 Polyunsaturated Fatty Acids in Dogs

  1999cited by this paper
• Endothelial dysfunction in human disease.

  1999cited by this paper
• Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs.

  1999cited by this paper
• Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.

  1999cited by this paper
• Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.

  1999cited by this paper
• Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients.

  1999cited by this paper
• Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease.

  1997cited by this paper
• Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction.

  1997cited by this paper
• The GISSI Story (1983–1996): A Comprehensive Review

  1997cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Dietary fish oil confers direct antiarrhythmic properties on the myocardium of rats.

  1996cited by this paper
• Statins do more than just lower cholesterol.

  1996cited by this paper
• Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease.

  1996cited by this paper
• The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

  1996cited by this paper
• Effects of dietary fish oil on ventricular premature complexes.

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy.

  1992cited by this paper
• A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

  1991cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells.

  1989cited by this paper
• Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners.

  1987cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper

• Prognostic value of secretoneurin in chronic heart failure. Data from the GISSI-Heart Failure trial.

  2023cites this paper
• Beta‐blocker use and mortality among patients with systolic heart failure and pacemaker rhythm

  2023cites this paper
• Marine-derived n-3 fatty acids therapy for stroke.

  2022cites this paper
• New Targets in Heart Failure Drug Therapy

  2021cites this paper
• LIPCAR Is Increased in Chronic Symptomatic HF Patients. A Sub-Study of the GISSI-HF Trial.

  2021cites this paper
• Coffee, Atrial Fibrillation, and Circulating Ceramides in Patients with Chronic Heart Failure.

  2021cites this paper
• Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

  2020cites this paper
• (Beneficial properties of omega-3 fatty acids in human disease)

  2020cites this paper
• Omega-3 gantz-azidoen propietate onuragarriak zenbait egoera klinikotan

  2020cites this paper
• Update: Therapie der chronischen Herzinsuffizienz

  2020cites this paper
• Cancer in chronic heart failure patients in the GISSI-HF trial.

  2020cites this paper
• Fish , fish oils , n-3 polyunsaturated fatty acids & cardiovascular health

  2020cites this paper
• Update: Therapie der chronischen Herzinsuffizienz

  2020cites this paper
• Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis

  2019cites this paper
• Update: Therapie der chronischen Herzinsuffizienz

  2019cites this paper
• University of Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults

  2019cites this paper
• Marine-derived n-3 fatty acids therapy for stroke.

  2019cites this paper
• Modes of death and prognostic outliers in chronic heart failure

  2019cites this paper
• Targeting Mitochondria for Therapy of Cardiovascular Disease

  2019cites this paper
• Update: Therapie der chronischen Herzinsuffizienz

  2019cites this paper
• Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

  2018cites this paper
• Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.

  2018cites this paper
• Update: Therapie der chronischen Herzinsuffizienz

  2018cites this paper
• Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.

  2018cites this paper
• Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

  2018cites this paper
• Circulating microRNA‐132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure

  2018cites this paper
• University of Groningen Lipids , inflammation , and the Renin-Angiotensin System

  2018cites this paper
• Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update

  2018cites this paper
• Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF.

  2017cites this paper
• Precision Nutrition and Omega-3 Polyunsaturated Fatty Acids: A Case for Personalized Supplementation Approaches for the Prevention and Management of Human Diseases

  2017cites this paper
• Marine‐derived n‐3 fatty acids therapy for stroke

  2017cites this paper
• Omega-3-Fettsäuren bei Herzinsuffizienz

  2017influential citation
• Publishing in a heart failure journal—where lies the scientific interest?

  2017cites this paper
• Omega-3-Fettsäuren bei Herzinsuffizienz

  2017cites this paper
• A low plasma 1,25(OH)2 vitamin D/PTH (1-84) ratio predicts worsening of renal function in patients with chronic heart failure.

  2016cites this paper
• Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial

  2016cites this paper
• Contributory risk and Management of Comorbidities of Hypertension, obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure

  2016cites this paper
• Pharmacological interventions for heart failure in people with chronic kidney disease.

  2016cites this paper
• Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HF.

  2016cites this paper
• Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association.

  2016cites this paper
• Omega-3 Fatty Acids Improve Lipid Metabolism and Inflammatory Markers in Patients with Heart Failure Undergoing Exercise Training

  2015cites this paper
• Should the pharmacological actions of dietary fatty acids in cardiometabolic disorders be classified based on biological or chemical function?

  2015cites this paper
• A quantitative QT hysteresis model

  2014cites this paper
• Specificity of the moving average method for detecting alternans

  2014cites this paper
• The cardiokine secreted Frizzled‐related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure

  2014cites this paper
• Should patients perception of health status be integrated in the prognostic assessment of heart failure patients? A prospective study

  2014cites this paper
• Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality.

  2013cites this paper
• n-3 PUFAs and heart failure.

  2013cites this paper
• Bibliography of One Hundred Key Papers

  2013cites this paper
• Miotoxicidad por estatinas en pacientes trasplantados cardiacos y utilidad de estudios genéticos para mejorar la seguridad de dichos fármacos

  2013cites this paper
• CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI‐HF trials

  2013cites this paper
• The role of n-3 polyunsaturated fatty acids in human heart failure.

  2013cites this paper
• Statin Therapy in Heart Failure: For Good, for Bad, or Indifferent?

  2013influential citation
• Targeting the Mitochondria in Cardiovascular Diseases

  2013cites this paper
• The Role of Statins in Diabetes Treatment

  2013cites this paper
• Cardioprotective effect of selenium via modulation of cardiac ryanodine receptor calcium release channels in diabetic rat cardiomyocytes through thioredoxin system.

  2013cites this paper
• Omega-3 Fatty Acids in Prevention of Cardiovascular Disease in Humans

  2013cites this paper
• Should We Start Prescribing Omega-3 Polyunsaturated Fatty Acids in Chronic Heart Failure?

  2012cites this paper
• Why Do We Still Need Large Scale Clinical Trial: The Case of n−3 PUFA

  2012cites this paper
• Pentraxin‐3 in chronic heart failure: the CORONA and GISSI‐HF trials

  2012cites this paper
• Пациенты старческого возраста с ИБС и хронической сердечной недостаточностью. Результаты применения

  2012cites this paper
• Use of implantable cardioverter defibrillator and cardiac resynchronization therapy: an Italian survey study on 220 cardiology departments

  2012cites this paper
• Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis.

  2012cites this paper
• [Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine].

  2012cites this paper
• HMG-CoA Reductase Inhibitors in Chronic Heart Failure

  2012cites this paper
• Reporting of Short-Term Clinical Outcomes After Esophagectomy: A Systematic Review

  2012cites this paper
• Nutritional assessment in heart failure patients.

  2011cites this paper
• Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial.

  2011cites this paper
• Statins and Intracerebral Hemorrhage Collaborative Systematic Review and Meta-Analysis

  2011cites this paper
• Statins in non‐ischaemic cardiomyopathy: an update on our current clinical and pathophysiological understanding

  2011cites this paper
• Statins and Intracerebral Hemorrhage: Collaborative Systematic Review and Meta-Analysis

  2011cites this paper
• Beneficio clínico de las estatinas: ¿hemos cubierto todo el espectro?

  2011cites this paper
• Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study.

  2011cites this paper
• Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials

  2011cites this paper
• Revascularization for patients with heart failure. Inconsistencies between theory and practice

  2011cites this paper
• Rational of Current Practice of Prescribing Statin to Treat Dyslipidaemia as Primary Prevention of Coronary Heart Disease in Elderly People

  2011cites this paper
• Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure: Data From the GISSI-Heart Failure Trial

  2010cites this paper
• Bioenergetics and Metabolic Changes in the Failing Heart

  2010cites this paper
• Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial.

  2010cites this paper
• Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA)

  2010cites this paper
• The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI‐heart failure (GISSI‐HF) trial

  2010cites this paper
• Antioxidant treatment protects diabetic rats from cardiac dysfunction by preserving contractile protein targets of oxidative stress.

  2010cites this paper
• Mortality and morbidity of newly diagnosed heart failure treated with statins: a propensity-adjusted cohort study.

  2010cites this paper
• Regulation of Kinin Receptor Expression in Heart Failure with a Focus on Vascular Endothelium

  2010cites this paper
• Ácidos grasos omega-3 y prevención cardiovascular

  2010cites this paper
• Prognostic value of chromogranin A in chronic heart failure: data from the GISSI‐Heart Failure trial

  2010cites this paper
• N-3 polyunsaturated fatty acids in heart failure: mechanisms and recent clinical evidence.

  2010cites this paper
• Effects of Statins and n–3 Fatty Acids on Heart and Brain Tissues: The Clash of the Titans

  2009cites this paper
• Statin use in chronic heart failure: waiting for the results of large prospective outcome trials.

  2009cites this paper
• Use of red blood cell fatty-acid profiles as biomarkers in cardiac disease.

  2009cites this paper
• Automated QT Measurement and Application to Detection of Moxifloxacin‐Induced Changes

  2009cites this paper
• Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome.

  2009cites this paper
• Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.

  2009cites this paper
• Effets des acides gras Oméga-3 sur la Cardioprotection: Etude des acides gras oméga-3 chez le rat et chez des patients porteurs d'un défibrillateur automatique implantable

  2009cites this paper
• Pleiotropic effects of statin therapy

  2009cites this paper
• Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial.

  2009cites this paper
• [Update on geriatric cardiology].

  2009cites this paper
• [The role of statins in the treatment of heart failure].

  2009cites this paper
• N-3 polyunsaturated fatty acids and statins in heart failure.

  2009cites this paper
• [Advances in heart failure].

  2009cites this paper